Artal Group S.A. Tcr2 Therapeutics Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	BUY	$20.38 - $34.07 $5.1 Million - $8.52 Million	250,000 Added 50.0%	750,000 $16.6 Million
Q3 2020 Nov 13, 2020	BUY	$13.1 - $20.69 $1.97 Million - $3.1 Million	150,000 Added 42.86%	500,000 $10.2 Million
Q2 2020 Aug 14, 2020	SELL	$6.51 - $16.85 $325,500 - $842,500	-50,000 Reduced 12.5%	350,000 $5.38 Million
Q4 2019 Feb 13, 2020	SELL	$12.17 - $17.88 $874,365 - $1.28 Million	-71,846 Reduced 15.23%	400,000 $5.71 Million
Q3 2019 Nov 14, 2019	SELL	$10.15 - $19.53 $184,263 - $354,547	-18,154 Reduced 3.7%	471,846 $7.09 Million
Q1 2019 May 10, 2019	BUY	$15.01 - $22.15 $7.35 Million - $10.9 Million	490,000 New	490,000 $8.54 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.